Inventiva Stock Bounces Back 3.88% in Oversold Territory: A Technical Signal to Watch
The stock of the biotech company from Lille gains 3.88% this Friday morning to €4.555, after having closed the previous day at €4.39. This rebound occurs in a context of a weekly decline of 3.5%, while the CAC 40 is slightly up by 0.26% at 8267 points during the session.
Inventiva's Notable Rebound to €4.555
This Friday, Inventiva's stock exhibits a notable rebound to €4.555, barely crossing the support threshold identified at €4.39. This level corresponds to the previous day's closing price and the lower boundary of the Bollinger Bands (€4.37), a zone that usually signals a potential oversold situation. The stock is thus trading at the bottom of the band, only 15% above the lower boundary, far from the upper boundary set at €5.64.
The RSI, a momentum indicator that measures the speed and magnitude of price movements, is at 29, just below the conventional threshold of 30, reinforcing the diagnosis of an oversold zone. This technical level could explain the bullish movement observed this morning, in a context where the three-month performance remains positive at +11.23% and where the stock has gained more than 70% over one year. The nearest resistance is at €5.79, about 27% above the current price.
Despite Today's Rebound, Inventiva Remains Below Short and Medium-Term Moving Averages
Despite today's rebound, Inventiva remains significantly behind its short and medium-term moving averages. The price is below the 20-day moving average (€5.00) and the 50-day moving average (€5.22), indicating a bearish trend over recent weeks. Only the 200-day moving average, established at €4.15, remains below the current price, preserving the long-term bullish trend.
The biopharmaceutical company, specializing in the development of treatments for fibrotic and metabolic diseases, will publish its first quarter 2026 revenue on May 25th. This event will be a focal point for monitoring the progress of its clinical programs. In the health sector, comparables are also up this morning: Sanofi is up 0.52% and UCB advances by 0.96% in session, in a generally stable European context.
